Literature DB >> 33432045

Cystoscopic hydrodistention characteristics provide clinical and long-term prognostic features of interstitial cystitis after treatment.

Wan-Ru Yu1, Jia-Fong Jhang2, Han-Chen Ho3, Yuan-Hong Jiang2, Cheng-Ling Lee2, Yung-Hsiang Hsu4, Hann-Chorng Kuo5.   

Abstract

To evaluate the correlations of clinical symptoms, urodynamic parameters, and long-term treatment outcomes with different findings of cystoscopic hydrodistention (HD) in patients with interstitial cystitis/bladder pain syndrome (IC/BPS). This retrospective analysis of 486 patients with IC/BPS investigated baseline clinical symptoms, disease duration, medical comorbidities, urodynamic findings, cystoscopic characteristics [including maximal bladder capacity (MBC) and the presence of glomerulations and Hunner's lesions], and outcomes according to the five IC/BPS HD subtypes based on the glomerulation grade, MBC, and the presence of Hunner's lesions. Receiver operation characteristic analysis identified an optimal cutoff value of MBC ≥ 760 ml as a predictor of satisfactory outcomes. Glomerulation grade and MBC were significantly correlated (r =  - 0.403, P < 0.001), and both were significantly associated with IC Symptom Index scores. The rate of satisfactory outcomes was better for the patients with low glomerulation grade and MBC ≥ 760 ml (64.2%), and significantly worse for those with Hunner's lesions (36.8%); no significant differences were noted among the other groups. The results suggested that IC/BPS patients can be classified into the following three distinct subgroups: (1) those with low glomerulation grade and MBC ≥ 760 ml; (2) those with low glomerulation grade and MBC < 760 ml, or with high glomerulation grade regardless of MBC; and (3) those with Hunner's lesions. The results showed that three IC/BPS subgroups had distinct bladder characteristics and treatment outcomes. The patients with high MBC and low glomerulation grade after HD had more medical comorbidities but a significantly higher rate of satisfactory treatment outcome.IRB: 105-25-B.

Entities:  

Year:  2021        PMID: 33432045      PMCID: PMC7801576          DOI: 10.1038/s41598-020-80252-x

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  28 in total

1.  Comparison of cystoscopic and histological findings in patients with suspected interstitial cystitis.

Authors:  M A Denson; T L Griebling; M B Cohen; K J Kreder
Journal:  J Urol       Date:  2000-12       Impact factor: 7.450

2.  Mapping of pain phenotypes in female patients with bladder pain syndrome/interstitial cystitis and controls.

Authors:  Dean A Tripp; J Curtis Nickel; Jennifer Wong; Michel Pontari; Robert Moldwin; Robert Mayer; Lesley K Carr; Ragi Doggweiler; Claire C Yang; Nagendra Mishra; Jorgen Nordling
Journal:  Eur Urol       Date:  2012-05-18       Impact factor: 20.096

3.  Bladder Capacity is a Biomarker for a Bladder Centric versus Systemic Manifestation in Interstitial Cystitis/Bladder Pain Syndrome.

Authors:  Stephen J Walker; João Zambon; Karl-Erik Andersson; Carl D Langefeld; Catherine A Matthews; Gopal Badlani; Heather Bowman; Robert J Evans
Journal:  J Urol       Date:  2017-02-12       Impact factor: 7.450

4.  Interstitial cystitis/painful bladder syndrome and associated medical conditions with an emphasis on irritable bowel syndrome, fibromyalgia and chronic fatigue syndrome.

Authors:  J Curtis Nickel; Dean A Tripp; Michel Pontari; Robert Moldwin; Robert Mayer; Lesley K Carr; Ragi Doggweiler; Claire C Yang; Nagendra Mishra; Jorgen Nordling
Journal:  J Urol       Date:  2010-08-17       Impact factor: 7.450

5.  Clinical phenotyping of women with interstitial cystitis/painful bladder syndrome: a key to classification and potentially improved management.

Authors:  J Curtis Nickel; Daniel Shoskes; Karen Irvine-Bird
Journal:  J Urol       Date:  2009-05-17       Impact factor: 7.450

Review 6.  Recent developments in the management of interstitial cystitis.

Authors:  Kirsten Bouchelouche; Joergen Nordling
Journal:  Curr Opin Urol       Date:  2003-07       Impact factor: 2.309

Review 7.  Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal.

Authors:  Joop P van de Merwe; Jørgen Nordling; Pierre Bouchelouche; Kirsten Bouchelouche; Mauro Cervigni; L Kurosch Daha; Suzy Elneil; Magnus Fall; Gero Hohlbrugger; Paul Irwin; Svend Mortensen; Arndt van Ophoven; John L Osborne; Ralph Peeker; Benedikte Richter; Claus Riedl; Jukka Sairanen; Martina Tinzl; Jean-Jacques Wyndaele
Journal:  Eur Urol       Date:  2007-09-20       Impact factor: 20.096

8.  Organ cross talk modulates pelvic pain.

Authors:  Charles N Rudick; Michael C Chen; Anne K Mongiu; David J Klumpp
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2007-07-11       Impact factor: 3.619

Review 9.  Sympathetic nervous system dysfunction in fibromyalgia, chronic fatigue syndrome, irritable bowel syndrome, and interstitial cystitis: a review of case-control studies.

Authors:  Laura-Aline Martínez-Martínez; Tania Mora; Angélica Vargas; Mario Fuentes-Iniestra; Manuel Martínez-Lavín
Journal:  J Clin Rheumatol       Date:  2014-04       Impact factor: 3.517

10.  Clinical guidelines for interstitial cystitis and hypersensitive bladder updated in 2015.

Authors:  Yukio Homma; Tomohiro Ueda; Hikaru Tomoe; Alex Tl Lin; Hann-Chorng Kuo; Ming-Huei Lee; Seung-June Oh; Joon Chul Kim; Kyu-Sung Lee
Journal:  Int J Urol       Date:  2016-05-24       Impact factor: 3.369

View more
  7 in total

1.  Use of Urinary Cytokine and Chemokine Levels for Identifying Bladder Conditions and Predicting Treatment Outcomes in Patients with Interstitial Cystitis/Bladder Pain Syndrome.

Authors:  Wan-Ru Yu; Yuan-Hong Jiang; Jia-Fong Jhang; Hann-Chorng Kuo
Journal:  Biomedicines       Date:  2022-05-17

2.  Can We Use Urinary Cytokine/Chemokine Analysis in Discriminating Ulcer-Type Interstitial Cystitis/Bladder Pain Syndrome?

Authors:  Yuan-Hong Jiang; Jia-Fong Jhang; Hann-Chorng Kuo
Journal:  Diagnostics (Basel)       Date:  2022-04-27

Review 3.  Low-Energy Shock Wave Plus Intravesical Instillation of Botulinum Toxin A for Interstitial Cystitis/Bladder Pain Syndrome: Pathophysiology and Preliminary Result of a Novel Minimally Invasive Treatment.

Authors:  Yuan-Hong Jiang; Jia-Fong Jhang; Yu-Khun Lee; Hann-Chorng Kuo
Journal:  Biomedicines       Date:  2022-02-07

4.  Therapeutic Efficacy of Intravesical Platelet-Rich Plasma Injections for Interstitial Cystitis/Bladder Pain Syndrome-A Comparative Study of Different Injection Number, Additives and Concentrations.

Authors:  Yuan-Hong Jiang; Jia-Fong Jhang; Teng-Yi Lin; Han-Chen Ho; Yung-Hsiang Hsu; Hann-Chorng Kuo
Journal:  Front Pharmacol       Date:  2022-03-22       Impact factor: 5.810

5.  Urine Oxidative Stress Biomarkers as Novel Biomarkers in Interstitial Cystitis/Bladder Pain Syndrome.

Authors:  Yuan-Hong Jiang; Jia-Fong Jhang; Han-Chen Ho; Dan-Yun Chiou; Hann-Chorng Kuo
Journal:  Biomedicines       Date:  2022-07-14

6.  Changes in Cystoscopic Findings after Intravesical Hyaluronic Acid Instillation Therapy in Patients with Interstitial Cystitis.

Authors:  Chia-Ju Lin; Chih-Ku Liu; Hsiao-Yun Hsieh; Ming-Jer Chen; Ching-Pei Tsai
Journal:  Diagnostics (Basel)       Date:  2022-08-19

7.  Usefulness of Urinary Biomarkers for Assessing Bladder Condition and Histopathology in Patients with Interstitial Cystitis/Bladder Pain Syndrome.

Authors:  Yuan-Hong Jiang; Jia-Fong Jhang; Yuan-Hsiang Hsu; Hann-Chorng Kuo
Journal:  Int J Mol Sci       Date:  2022-10-10       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.